Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 24, Number 3—March 2018

Letter

Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017

On This Page

Article Metrics

Altmetric:

Citations:

Views: Views equals page views plus PDF downloads

Metric Details

Cite This Article

Close

Highlight and copy the desired format.

EID Katz AR. Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis. 2018;24(3):608. https://dx.doi.org/10.3201/eid2403.171892
AMA Katz AR. Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017. Emerging Infectious Diseases. 2018;24(3):608. doi:10.3201/eid2403.171892.
APA Katz, A. R. (2018). Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017. Emerging Infectious Diseases, 24(3), 608. https://dx.doi.org/10.3201/eid2403.171892.

To the Editor: I read with great interest the report by Lefebvre et al. about a Neisseria gonorrhoeae isolate identified in Canada demonstrating a ceftriaxone MIC of 1 mg/L (1). The authors note: “As of October 15, 2017, only 5 ceftriaxone-resistant Neisseria gonorrhoeae isolates had been reported worldwide (MIC range 0.5–2 mg/L).” The authors cite published reports from Spain, Japan, Australia, and France.

I would like to clarify that additional N. gonorrhoeae isolates have been identified with ceftriaxone MICs >0.5 mg/L. Since 1987, as part of the Gonococcal Isolate Surveillance Project, the Centers for Disease Control and Prevention has been testing N. gonorrhoeae isolates for ceftriaxone susceptibility. During 1987–2016, the Centers for Disease Control and Prevention identified and reported 5 isolates with ceftriaxone MICs of 0.5 mg/L in the United States. These isolates were found in San Diego, California (1987); Cincinnati, Ohio (1992 and 1993); Philadelphia, Pennsylvania (1997); and most recently, Oklahoma City, Oklahoma (2012) (2). Therefore, although the number of N. gonorrhoeae isolates with ceftriaxone MICs >0.5 mg/L identified globally to date has been small, these Gonococcal Isolate Surveillance Project findings should be acknowledged. Continued and enhanced global surveillance of gonococcal isolates for antimicrobial susceptibility testing is imperative.

Top

Alan R. KatzComments to Author 

Author affiliation: University of Hawaii, Honolulu, Hawaii, USA

Top

References

  1. Lefebvre B, Martin I, Demczuk W, Deshaies L, Michaud S, Labbé AC, et al. Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis. 2018;24:3813. DOIPubMed
  2. Centers for Disease Control and Prevention. Sexually transmitted diseases surveillance 2016 [cited 2017 Nov 19]. https://www.cdc.gov/std/stats16/CDC_2016_STDS_Report-for508WebSep21_2017_1644.pdf

Top

Cite This Article

DOI: 10.3201/eid2403.171892

Related Links

Top

Table of Contents – Volume 24, Number 3—March 2018

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Alan R. Katz, University of Hawaii at Manoa, Office of Public Health Studies, Biomedical Sciences Bldg, Rm D104M, 1960 East-West Rd, Honolulu, HI 96822, USA


character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

TOP